GRIDD Phases & Outcomes

The GRIDD project, launched in 2017, is comprised of 5 unique phases that collectively will  produce benefits that will endure for generations to come.

The implementation of each phase will result in a new GRIDD methodology called Global Research of Impact on Patients (GRIP),  a novel Patient-Reported Impact of Dermatological Diseases (PRIDD) measurement tool, as well as a dataset that will help transform the way the world sees and addresses dermatological diseases. 

Learn about all the phases below and see where we are today!

Image

Click on the image to enlarge.

Click to expand the below table by each phase.

GRIDD Project Timeline: 2017 – 2022

Phase 1 - A Systematic review of published patient-reported outcomes (PRO) measures of the life impact of dermatology diseases and expanded the patient-centred item (impact) identification inventory. Design and implement the GRIP methodology. >

Phase 1

2018-2019

 

 

 

 

 

 

MAIN OUTCOMES

Systematic Literature Review - Completed

  •  Engaged with leading academic institutions and their experts to co-lead the GRIDD project.

  •  Conducted a systematic literature review of 12,957 existing patient-centered outcome measures used in dermatology using databases including PubMed; Embase; PsychInfo; Cinhal. Findings from this systematic literature review revealed that existing measures used both in research and clinical settings don’t meet the scientific standards.

  •  59 generic, 23 dermatology-specific and 149 disease-specific patient-reported outcomes (PROs) used in dermatology research and practice were identified. None met COSMIN Standard A

  •  Initiated a patient-centred item (impact) identification inventory

  •  Publish results

The results from GRIDD Phase 1 Systematic Literature Review (2017-2018) found that existing patient-impact measurement tools (questionnaires) used in both dermatology research and clinical settings don’t meet the commonly accepted scientific standards. This means there is currently no COSMIN A Standard for dermatology.GRIDD will address this gap with PRIDD: the A Standard patient-impact measurement tool that will provide the data for many applications including elevating dermatology in the global disease rankings;
allowing the integration of the patient’s voice in dermatology care and treatments and ultimately provide those with dermatology conditions worldwide a better quality of life.